<DOC>
	<DOCNO>NCT01368445</DOCNO>
	<brief_summary>The Purpose study evaluate safety efficacy MP03-36 ( 0.15 % azelastine hydrochloride ) dosages 2 spray per nostril daily 2 spray per nostril twice daily patient seasonal allergic rhinitis .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Nasal Spray Treat Seasonal Allergies</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Male female patient 12 year age old Provide write informed consent/pediatric assent . If patient minor , parent legal guardian must give write informed consent Screening Visit : Have 12hour reflective total nasal symptom score ( TNSS ) least 8 possible 12 congestion score 2 3 Day 7 Randomization Visit : Have 12hour reflective total nasal symptom score ( TNSS ) ( AM PM ) least 8 3 separate assessment ( one within 2 day Day 1 , include morning Day 1 ) Leadin Period . In addition , AM PM nasal congestion score 2 3 must record 3 separate assessment ( one within 2 day Day 1 , include morning Day 1 ) . Must take least 10 dos study medication leadin period Randomization Visit : An instantaneous ( TNSS ) ≥ 8 begin onset action assessment Day 1 Willing able comply study requirement At least 2year history seasonal allergic rhinitis ( SAR ) fall pollen allergy season The presence IgEmediated hypersensitivity local fall pollen confirm positive response either skin prick intradermal test within last year . A positive response define wheal diameter least 3 mm large control skin prick test least 7 mm large control intradermal test . General good health free disease concomitant treatment could interfere interpretation study result determine investigator sponsor 's medical officer Patients receive immunotherapy injection ( antigen desensitization ) must stable maintenance regimen least 30 day first study visit ( adjustment regimen follow brief period miss injection preclude participation ) . Patients maintenance dose sublingual immunotherapy may consider trial casebycase basis discussion sponsor 's medical monitor designee . The use investigational drug within 30 day prior Day 7 . No investigational product permit use conduct study Presence hypersensitivity drug similar azelastine either sorbitol sucralose ( Splenda® brand sweetener ) Women pregnant nursing Women childbearing potential abstinent practice medically acceptable method contraception Respiratory tract infection within two week prior Day 7 Respiratory Infections require oral antibiotic treatment two week prior Day 7 Other nasal disease ( ) likely affect deposition intranasal medication , sinusitis , rhinitis medicamentosa clinically significant polyposis nasal structural abnormality Patients asthma ( exception mild , intermittent asthma ) Patients significant pulmonary disease Patients known history alcohol drug abuse Existence surgical medical condition , opinion investigator sponsor , might significantly alter absorption , distribution , metabolism , excretion study drug Clinically relevant abnormal physical finding within 1 week randomization , opinion investigator , would interfere objective study may preclude compliance study procedure Planned travel outside study area study period Family member employee exclude Patients receive prohibited medication within specified timepoints protocol .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>